Literature DB >> 18844463

Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.

Vinod Trivedi1, Jana Von Lindern, Miguel Montes-Walters, Daniel R Rojo, Elisabeth J Shell, Neil Parkin, William A O'Brien, Monique R Ferguson.   

Abstract

The role specific reverse transcriptase (RT) drug resistance mutations play in influencing phenotypic susceptibility to RT inhibitors in virus strains with complex resistance interaction patterns was assessed using recombinant viruses that consisted of RT-PCR-amplified pol fragments derived from plasma HIV-1 RNA from two treatment-experienced patients. Specific modifications of key RT amino acids were performed by site-directed mutagenesis. A panel of viruses with defined genotypic resistance mutations was assessed for phenotypic drug resistance. Introduction of M184V into several different clones expressing various RT resistance mutations uniformly decreased susceptibility to abacavir, lamivudine, and didanosine, and increased susceptibility to zidovudine, stavudine, and tenofovir; replication capacity was decreased. The L74V mutation had similar but slightly different effects, contributing to decreased susceptibility to abacavir, lamivudine, and didanosine and increased susceptibility to zidovudine and tenofovir, but in contrast to M184V, L74V contributed to decreased susceptibility to stavudine. In virus strains with the nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations K101E and G190S, the L74V mutation increased replication capacity, consistent with published observations, but replication capacity was decreased in strains without NNRTI resistance mutations. K101E and G190S together tend to decrease susceptibility to all nucleoside RT inhibitors, but the K103N mutation had little effect on nucleoside RT inhibitor susceptibility. Mutational interactions can have a substantial impact on drug resistance phenotype and replication capacity, and this has been exploited in clinical practice with the development of fixed-dose combination pills. However, we are the first to report these mutational interactions using molecularly cloned recombinant strains derived from viruses that occur naturally in HIV-infected individuals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18844463      PMCID: PMC2721781          DOI: 10.1089/aid.2007.0244

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  60 in total

1.  Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.

Authors:  C Dykes; K Fox; A Lloyd; M Chiulli; E Morse; L M Demeter
Journal:  Virology       Date:  2001-07-05       Impact factor: 3.616

2.  In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.

Authors:  N A Margot; J M Waters; M D Miller
Journal:  Antimicrob Agents Chemother       Date:  2006-09-18       Impact factor: 5.191

3.  Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.

Authors:  Jeannette M Whitcomb; Wei Huang; Kay Limoli; Ellen Paxinos; Terri Wrin; Gail Skowron; Steven G Deeks; Michael Bates; Nicholas S Hellmann; Christos J Petropoulos
Journal:  AIDS       Date:  2002-10-18       Impact factor: 4.177

4.  The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.

Authors:  Richard H Haubrich; Carol A Kemper; Nicholas S Hellmann; Philip H Keiser; Mallory D Witt; Donald N Forthal; John Leedom; Matthew Leibowitz; Jeannette M Whitcomb; Douglas Richman; J Allen McCutchan
Journal:  AIDS       Date:  2002-10-18       Impact factor: 4.177

5.  Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.

Authors:  Robert T Schooley; Peter Ruane; Robert A Myers; Gildon Beall; Harry Lampiris; Daniel Berger; Shan-Shan Chen; Michael D Miller; Erica Isaacson; Andrew K Cheng
Journal:  AIDS       Date:  2002-06-14       Impact factor: 4.177

6.  Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.

Authors:  Jean-Luc Meynard; Muriel Vray; Laurence Morand-Joubert; Esther Race; Diane Descamps; Gilles Peytavin; Sophie Matheron; Claire Lamotte; Sonia Guiramand; Dominique Costagliola; Françoise Brun-Vézinet; François Clavel; Pierre-Marie Girard
Journal:  AIDS       Date:  2002-03-29       Impact factor: 4.177

7.  Long-term benefit of genotypic-guided therapy and prevalence of multinucleoside resistance in an Italian group of antiretroviral multiexperienced patients.

Authors:  E Quiros-Roldan; F Moretti; M Airoldi; C Fausti; A Chiodera; F Castelli; G Carosi
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

8.  Antiretroviral-drug resistance among patients recently infected with HIV.

Authors:  Susan J Little; Sarah Holte; Jean-Pierre Routy; Eric S Daar; Marty Markowitz; Ann C Collier; Richard A Koup; John W Mellors; Elizabeth Connick; Brian Conway; Michael Kilby; Lei Wang; Jeannette M Whitcomb; Nicholas S Hellmann; Douglas D Richman
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

9.  Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies.

Authors:  Louis M Mansky; Dennis K Pearl; Lisa C Gajary
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Lisa K Naeger; Nicolas A Margot; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

View more
  3 in total

1.  The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.

Authors:  J Wang; H Liang; L Bacheler; H Wu; K Deriziotis; L M Demeter; C Dykes
Journal:  Virology       Date:  2010-04-18       Impact factor: 3.616

2.  Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

Authors:  Paul E Sax; Camlin Tierney; Ann C Collier; Eric S Daar; Katie Mollan; Chakra Budhathoki; Catherine Godfrey; Nasreen C Jahed; Laurie Myers; David Katzenstein; Awny Farajallah; James F Rooney; Belinda Ha; William C Woodward; Judith Feinberg; Karen Tashima; Robert L Murphy; Margaret A Fischl
Journal:  J Infect Dis       Date:  2011-10-15       Impact factor: 5.226

3.  Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.

Authors:  Gert U Van Zyl; Tommy F Liu; Mathilda Claassen; Susan Engelbrecht; Tulio de Oliveira; Wolfgang Preiser; Natasha T Wood; Simon Travers; Robert W Shafer
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.